gp120/cd4

(4S,5S)-(+)-Germacrone-4,5-epoxide inhibits certain subtypes of cytochrome P450 (CYP).

Ingenol mebutate (Ingenol 3-Angelate) 是 PKC 的有效激动剂，包括 PKC-α、PKC-β、PKC-γ、PKC-δ 和 PKC-ε，Kis 为 0.3、0.105、0.162、0.376 和 0.171 nM。 Ingenol mebutate 具有抗炎和抗肿瘤活性。

Physalin H is an Hh signaling inhibitor blocks GLI1-DNA-complex formation, it also strong quinone reductase induction activity with IR (Induction ratio, QR induction activity) value of 3.74±0.02. Physalin H shows immunosuppressive effects on T cells both

BMS-378806 (BMS-806) 是一种 HIV-1 抑制剂，可选择性抑制 HIV-1 gp120 结合到 CD4 受体，EC50为 0.85-26.5 nM。

Moringin 是一种异硫氰酸酯，由 Moringa oleifera 种子中存在的硫代葡萄糖苷前体 glucoMoringin 通过黑芥子酶介导水解获得。Moringin 具有抗炎和抗氧化特性。

Anti-mouse CD4-InVivo 一种抗小鼠 CD4 抗体抑制剂，可用于生命科学领域的相关研究，其产品编号为 T35388。

YYA-021具有高抗HIV 活性和低细胞毒性，是一种抑制HIV 进入的小分子CD4模拟物,。

3,5,6,7,8,3',4'-Heptemthoxyflavone 是来自蜜柑皮中的黄酮，具有抗肿瘤起始活性和抗神经炎症作用。它能通过 cAMP ERK CREB 信号诱导脑源性神经营养因子表达，降低 C6 细胞磷酸二酯酶活性。它能抑制胶原酶的活性，增加人真皮成纤维细胞新生细胞中 I 型前胶原含量。

Peptide T acetate(106362-32-7 free base) 是一种来自 HIV-1 gp120 V2 区域的八肽。它是一种合成八肽，其可能的作用机制是 gp120 对 CD4 受体的竞争性抑制以及与血管肠肽受体的结合和抑制细胞因子作用。

NBD-556是一种 CD4 模拟物，识别 HIV-1 包膜蛋白 gp120 并诱导 gp120 重组，类似于 CD4 结合，可阻断 gp120-CD4 的相互作用。

Temsavir (BMS626529) 是一种新型附着抑制剂，靶向 HIV-1 gp120 并阻止其与 CD4+ T 细胞结合。

Peptide T (TFA) is an octapeptide derived from the V2 region of HIV-1 gp120. It serves as a ligand for the CD4 receptor, effectively inhibiting the binding of HIV to the CD4 receptor.

Defensin HNP-3 is a peptide secreted by human polymorphonuclear leukocytes (PMNs) that has antimicrobial properties. It induces lysis of mammalian cells when used at a concentration of 25 μg mL. It also inhibits growth of E. faecalis (ED50 = 100 nM) and clinical isolates of P. aeruginosa (MIC90 = 4 μM). HNP-3 binds to recombinant HIV-1 envelope glycoprotein (gp120) and human CD4 (Kds = 52.8 and 34.9 nM, respectively). It also binds to recombinant, immobilized human surfactant protein D (SP-D; Kd = 55.7 nM) and inhibits focus formation in Madin-Darby canine kidney (MDCK) cells infected with influenza A virus (IAV).

Peptide T is an octapeptide from the V2 region of HIV-1 gp120. This synthetic octapeptide potentially functions through competitive inhibition of gp120 binding to the CD4 receptor, as well as interaction with vasointestinal peptide (VIP) receptors.

BMS-378806 is an orally bioavailable HIV-1 inhibitor that interferes with gp120-CD4 interaction.

CD4 (81-92) is a peptide that was previously found to inhibit gp120 binding, HIV-1 infectivity, and syncytium formation.

Complestatin is a compound extracted from Streptomyces lavendulae mycelia; on acid hydrolysis yields D-4-hydroxyphenylglycine & D-3,5-dichloro-4-hydroxyphenylglycine & acidic chromophore; inhibits gp120-CD4 binding. It is isolated from the culture broth of Streptomyces and has anti-HIV-1 activity. It has a role as a metabolite, an antimicrobial agent and an anti-HIV-1 agent.

DS-003是一种小分子Gp120抑制剂。作为BMS-378806的类似物，DS003在较长暴露时间及与融合抑制剂联合使用时显示出增强的抑制活性。然而，可溶性CD4+的预先暴露会阻碍DS003与病毒包膜的结合。研究表明，由于DS003针对Gp120的CD4+结合位点，它是预防暴露前预防治疗的有前途的候选化合物。

VRC-01 是一种人源IgG1抗体，专门靶向gp120（包膜糖蛋白）。其通过部分模拟CD4受体与HIV-1 gp120包膜糖蛋白进行互作，阻止病毒入侵。VRC-01 的同型对照可参见Human IgG1 kappa（Isotype Control）。

Retrocyclin-1是一种θ防御素，具有识别并结合含碳水化合物表面分子的能力，能够保护细胞抵御HIV-1感染。该化合物对胎球蛋白、gp120（Kd=35.4 nM）、CD4（Kd=31 nM）以及半乳糖神经酰胺（Kd=24.1 nM）展现出高度亲和性。

HIV Peptide T（Peptide T），这种合成的八肽是HIV感染治疗中的一种抗病毒药物，其主要通过竞争性抑制gp120（HIV表面蛋白）与CD4受体的相互作用，同时与血管肠肽（vasointestinal peptide, VIP）受体同源结合并且阻断细胞因子的产生与作用来发挥功效。

Fostemsavir (BMS-663068) 是 BMS-626529 的原药，可抑制 HIV-1 与细胞 CD4 受体的结合，能结合gp120。

Fostemsavir Tris (BMS-663068 Tris) 是一种 HIV-1附着抑制剂。

Feglymycin is a 13-amino acid peptide originally isolated from Streptomyces that has antibacterial and antiviral activities. It is active against Gram-positive bacteria (MICs = 32-64 μg/ml) and inhibits HIV viral replication in H9 cells (IC50 = ~5 μM). Feglymycin is also active against clinical isolates of HIV-1 from clades A-D, A/E, and G (EC50s = 0.5-6.7 μM). It interacts with gp120 and inhibits HIV-1 NL4.3 binding to human soluble CD4 (EC50 = 4.4 μM) and to CD4+ SupT1 T cells by 74.5% when used at a concentration of 10.5 μM. Feglymycin inhibits the E. coli peptidoglycan biosynthesis enzymes MurA and MurC (Kis = 3.4 and 0.3 μM, respectively) in a noncompetitive manner.